ArticleFolia microbiologica2026
Design, synthesis, and antimicrobial evaluation of heteroaromatic or acyl-substituted benzenesulfonamide-linked aminoquinolinequinones.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of aminated quinolonequinones (AQQ1-13) was synthesized from quinolinequinone and substituted aromatic amines containing a sulfonamide group with conformationally restricted heterocyclic structures or an acyl group. The obtained AQQs were characterized by various spectroscopic techniques including FTIR, NMR, and MS analyses. Structural modifications of the sulfonamide group in these compounds were selected by introducing various heterocyclic substituents, such as isoxazole, thiadiazole, pyridine, pyrimidine, pyrazine, and pyridazine, or by attaching acyl groups (acetyl or benzamide) with different substituents. Some of the synthesized AQQs exhibited antifungal activity against the tested strains, with potencies comparable to the reference drugs under the tested conditions. Noticeably, AQQ5 with thiadiazole moiety attached to the sulfonamide group showed inhibitory activity against C. albicans (MIC: 19.53 µg/mL). The most active compound AQQ5 also showed the best antifungal potency towards to other two fungi (C. parapsilosis and C. tropicalis). However, it should be noted that antifungal activity was evaluated only against ATCC strains. Considering the increasing prevalence of antifungal resistance, these results may not fully reflect the efficacy against clinical isolates. Antifungal resistance may render the antifungal activity already seen against ATCC strains ineffective in clinical isolates. Yet the putative target, farnesyl pyrophosphate synthase identified through in silico protocols suggests that farnesyl pyrophosphate synthase may be a potential target, warranting further experimental validation.
Indexed as
Identifiers
42033593What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.